| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047593573 |
| P356 | DOI | 10.2165/00003495-200363170-00003 |
| P698 | PubMed publication ID | 12921486 |
| P2093 | author name string | Hemant Pande | |
| Paul Thuluvath | |||
| P2860 | cites work | Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group | Q28288650 |
| Acute pancreatitis. | Q30490265 | ||
| Topical glyceryl trinitrate relaxes the sphincter of Oddi | Q33618026 | ||
| The role of infection in acute pancreatitis | Q33686178 | ||
| The potential role of therapeutic cytokine manipulation in acute pancreatitis | Q33724455 | ||
| Procedure-specific outcomes assessment for endoscopic retrograde cholangiopancreatography. | Q33737545 | ||
| Endoscopic retrograde cholangiopancreatography in the next millennium. | Q33807554 | ||
| Early trypsinogen activation in acute pancreatitis. | Q33953449 | ||
| Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial | Q34403293 | ||
| Endoscopic retrograde cholangiopancreatography | Q34426145 | ||
| Somatostatin and somatostatin analogues: diagnostic and therapeutic uses | Q34493829 | ||
| Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure | Q34525789 | ||
| Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice | Q35352336 | ||
| Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications | Q35361584 | ||
| Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. | Q36480446 | ||
| Experimental acute pancreatitis in dogs and effects of steroids. A light and electron microscopic study with reference to pathogenesis. | Q36606436 | ||
| Post-ERCP pancreatitis: reduction by routine antibiotics | Q40583289 | ||
| Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis | Q40735691 | ||
| Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade | Q40901894 | ||
| Effect of Calcitonin on the Serum Amylase Levels after Endoscopic Retrograde Cholangiopancreatography | Q40921457 | ||
| Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. | Q41010243 | ||
| Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. | Q41455584 | ||
| The role of cytokines in the pathogenesis of acute pancreatitis | Q41691435 | ||
| Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis | Q41778065 | ||
| Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography | Q42167184 | ||
| Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? | Q43529954 | ||
| Interleukin-10 attenuates proinflammatory cytokine production and improves survival in lethal pancreatitis | Q43555110 | ||
| Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury | Q43568320 | ||
| The role of glucagon in endoscopic cholangiopancreatography | Q43576575 | ||
| Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial | Q43650353 | ||
| Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis | Q43725537 | ||
| A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis | Q43738266 | ||
| Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia | Q43890192 | ||
| Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial | Q43940449 | ||
| Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility | Q43980746 | ||
| Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan | Q44072963 | ||
| Early NF-kappaB activation is associated with hormone-induced pancreatitis. | Q44131824 | ||
| Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial | Q44151711 | ||
| Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. | Q44856812 | ||
| Nitric oxide, heparin and procaine treatment in experimental ceruleine-induced acute pancreatitis in rats. | Q51443207 | ||
| Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. | Q52918160 | ||
| Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. | Q54584071 | ||
| A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis | Q61698868 | ||
| Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein | Q67700690 | ||
| Amylase, pancreatic isoamylase and lipase in serum before and after endoscopic pancreatography | Q68962174 | ||
| Does heparin modify protease-antiprotease balance in acute experimental pancreatitis in rats | Q68965955 | ||
| The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs | Q69192117 | ||
| Sodium taurocholate-induced acute pancreatitis in pigs. Pathomorphological studies of the pancreas in untreated animals and animals pretreated with high doses of corticosteroids or protease inhibitors | Q69460621 | ||
| Pathophysiology of acute pancreatitis: evaluation of the effect and mode of action of steroids in experimental pancreatitis in dogs | Q70389645 | ||
| Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis | Q70824669 | ||
| Use of corticosteroids in the prevention of post-ERCP pancreatitis | Q71172751 | ||
| Complications of endoscopic biliary sphincterotomy | Q71472169 | ||
| Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis | Q71563232 | ||
| Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study | Q71606044 | ||
| Acute pancreatitis | Q72094978 | ||
| Anti-neutrophil antibody attenuates the severity of acute lung injury in rats with experimental acute pancreatitis | Q72362718 | ||
| Acute pancreatitis | Q72384590 | ||
| Inflammatory mediators in acute pancreatitis | Q72609962 | ||
| Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography | Q72802055 | ||
| Prevention of post-ERCP pancreatitis | Q73334707 | ||
| Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography | Q73400320 | ||
| Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success? | Q73401752 | ||
| The role of immunocytes in acute and chronic pancreatitis: when friends turn into enemies | Q73509735 | ||
| Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models | Q74457024 | ||
| Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan | Q74457032 | ||
| The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury | Q74463023 | ||
| Risk factors for post-ERCP pancreatitis: a prospective, multicenter study | Q74568909 | ||
| Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study | Q77318987 | ||
| Mechanism of pancreatitis caused by ERCP | Q77388566 | ||
| Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial | Q77400030 | ||
| Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography | Q77654712 | ||
| Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis | Q77689105 | ||
| Pancreatitis, cytokines, and SIRS: déjà vu all over again? | Q77733696 | ||
| Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone | Q77879363 | ||
| P433 | issue | 17 | |
| P921 | main subject | cholangiopancreatography | Q64624681 |
| P304 | page(s) | 1799-1812 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis | |
| P478 | volume | 63 |
| Q34589730 | Antioxidative phytoceuticals to ameliorate pancreatitis in animal models: an answer from nature |
| Q46885136 | Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis |
| Q37353885 | Ectopic pancreaticobiliary drainage accompanied by proximal jejunal adenoma: a case report |
| Q34390035 | Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review |
Search more.